A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) — Stella
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(74 sites)
United States
University of California Irvine Medical Center, Orange, California
University of California, Davis Comprehensive Cancer Center, Sacramento, California
Stanford Cancer Institute, Stanford, California
University of Colorado Cancer Center, Aurora, Colorado
Georgetown University Medical Center, Washington D.C., District of Columbia
University of Miami; Sylvester Cancer Center, Miami, Florida
Winship Cancer Institute, Emory University, Atlanta, Georgia
University of Chicago Medical Center, Chicago, Illinois
John Hopkins University, Baltimore, Maryland
Massachusetts General Hospital, Boston, Massachusetts
Dana Farber Cancer Institute, Boston, Massachusetts
Henry Ford Cancer Institute, Detroit, Michigan
Washington University School of Medicine Siteman Cancer Center, St Louis, Missouri
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York
Memorial Sloan Kettering Cancer Center, New York, New York
Duke University Medical Center, Durham, North Carolina
OSU Brain & Spine Hospital, Columbus, Ohio
University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania
Sarah Cannon, Nashville, Tennessee
MD Anderson Cancer Center, Houston, Texas
Fred Hutchinson Cancer Center, Seattle, Washington
Australia
Royal North Shore Hospital, Sydney, New South Wales
Princess Alexandra Hospital, Woolloongabba, Queensland
Peter MacCallum Cancer Centre, Melbourne, Victoria